Page Title
Clinical Trial Finder
Ask About Participating in This Study
Restore CFTR ProteinClosed to Enrollment
RESTORE-CF: Phase 1/2 study of MRT5005 drug in adults with cystic fibrosis (Parts A, B and B Expansion), protocol number Translate Bio MRT5005-101The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Restore CFTR ProteinClosed to Enrollment
RESTORE-CF: Phase 1/2 study of MRT5005 drug in adults with cystic fibrosis (Parts A, B and B Expansion), protocol number Translate Bio MRT5005-101
This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.
-
Age:
18 Years and Older
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
50 to 90%
-
Number of Visits:
21
-
Length of Participation:
1 years
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More